She spent most of her life struggling to breathe. At 72, she finally got an answer.

A Houston woman was 72 years old when she learned she'd had a rare disorder her entire life. How was that possible?

Could 1 tiny biotech topple Vertex Pharmaceuticals' cystic fibrosis empire?

This risk is weighing on the stock.

Cystic fibrosis medication Alyftrek is now covered by Sask. government

Saskatchewan residents living with cystic fibrosis (CF) now have a new medication that can be life-changing. Alyftrek is a drug that improves lung function and controls symptoms. Advocates who pushed ...
DiscoverHumboldt.com

Saskatchewan adds Alyftrek to cystic fibrosis drug coverage

Saskatchewan residents living with cystic fibrosis now have access to provincial coverage for a new medication. As of Aug. 1, ...

Love You To Death - what happened to Lisa and Matthew after her arrest?

Now, Matthew Johnson breaks his silence in a groundbreaking documentary. This Wednesday (19 August), Channel 4 revisits the ...

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; ...

Son of 'Britain's most evil mum' says he holds no resentment

The Devon mum was jailed after pleading guilty to child cruelty ...

This Buzzy Supplement Claims It’ll Maximize Your Protein Intake. Here’s What Doctors Want You to Know.

Before you take digestive enzymes for gains, know what experts say they can—and can’t—do.

'Mum still believes she was right to fake my illness'

Ahead of a Channel 4 documentary, Lisa Hayden-Johnson's son Matthew reflects on her actions.

‘My mum faked my brother's illness - she should have spent longer in prison'

Lisa Hayden-Johnson subjected her son, Matthew, to needless medical procedures - now he and his sister have spoken out ...

Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of ...